Nanobiotix (NASDAQ:NBTX) Trading 12.5% Higher – Should You Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s stock price shot up 12.5% during mid-day trading on Wednesday . The company traded as high as $38.75 and last traded at $39.1010. 20,305 shares were traded during trading, a decline of 63% from the average session volume of 54,438 shares. The stock had previously closed at $34.77.

Analysts Set New Price Targets

A number of brokerages have issued reports on NBTX. Guggenheim boosted their price target on shares of Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, April 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research note on Tuesday, April 21st. UBS Group boosted their price target on shares of Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. Finally, TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $26.67.

Nanobiotix Stock Performance

The stock’s 50 day moving average is $31.89 and its two-hundred day moving average is $25.30.

Nanobiotix (NASDAQ:NBTX) last released its earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The company had revenue of $3.42 million for the quarter. As a group, analysts predict that Nanobiotix S.A. – Sponsored ADR will post 0.53 EPS for the current fiscal year.

Institutional Trading of Nanobiotix

A number of large investors have recently made changes to their positions in NBTX. Royal Bank of Canada increased its stake in shares of Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after buying an additional 2,500 shares during the period. Optiver Holding B.V. acquired a new position in Nanobiotix in the third quarter valued at approximately $101,000. Marshall Wace LLP acquired a new position in Nanobiotix in the fourth quarter valued at approximately $220,000. Finally, Millennium Management LLC acquired a new position in Nanobiotix in the fourth quarter valued at approximately $390,000. 38.81% of the stock is currently owned by hedge funds and other institutional investors.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.